IMP3-saRNA (YMN-136) Vaccine
2026-864
Phase 1 mab active
Quick answer
IMP3-saRNA (YMN-136) Vaccine for Non-Small Cell Lung Cancer is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Indication
- Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- mab
- Status
- active